Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771681 | 0.85 | TRPV1 (0.43) | FFAR1PPARAHDAC1HDAC2HDAC8 | |
| SCHEMBL5773998 | 0.85 | FFAR1 (0.46) | FFAR1FFAR4PPARGPPARAPPARD | |
| SCHEMBL5773606 | 0.83 | MAPT (0.48) | HDAC1MLYCD | |
| SCHEMBL5773472 | 0.83 | FFAR4 (0.50) | FFAR1FFAR4PPARGPPARAPPARD | |
| SCHEMBL5774948 | 0.83 | FFAR1 (0.51) | FFAR1RXRARXRBRXRG | |
| SCHEMBL5774472 | 0.83 | RXRA (0.50) | FFAR1RXRARXRBRXRG | |
| Trifluoroacetic Acid SCHEMBL5771101 | 0.82 | TP53 (0.46) | — | |
| SCHEMBL5772923 | 0.82 | TSHR (0.55) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL5772507 | 0.82 | RXRA (0.50) | FFAR1FFAR4PPARGPPARAPPARD | |
| SCHEMBL5776861 | 0.82 | PPARA (0.48) | FFAR1FFAR4PPARGPPARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | FFAR1 178/4885FFAR4 143/4885PPARG 480/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | FFAR1 90/4885FFAR4 145/4885PPARG 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.